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monia (VAP) still remains a common de-
vice-associated hospital acquired infection 
in pediatric and adult intensive care units. 
The aim of our study was to determine 
ways of microbial transmission to the low-
er airways in intubated patients admitted 
to a single tertiary-care pediatric intensive 
care unit.
Methods. This was a prospective obser-
vational study. A total of 284 sample sets 
(oropharyngeal swabs, swabs from the lu-
men of the proximal tip of an endotracheal 
tube, and bronchoalveolar lavage samples) 
were collected from 62 consecutive pedi-
atric patients intubated for > 24 hours. 
Pulsed-field gel electrophoresis was per-
formed on all isolated pathogens, which 
were later identified by MALDI biotyper 
(MALDI-TOF mass spectrometry).
Results. Overall colonization rates were 
high and did not differ significantly at 
different time points in the oropharynx 
(75%–100%) and the lower airways (50%–
76.5%). The endotracheal tube was colo-
nized at lower rates: on day 1–3 (28.8%), 
on day 4–6 (52.7%), on day 7–9 (61.8%) 
and on day 10-12 (52.9%) (P < 0.001). A 
total of 191 matched sample sets from the 
lower airways and at least one site above 
were collected from 46 (74.2%) patients. 
In the oropharynx-lower airways group, 
Candida spp. (76.9%) and upper airway 
bacteria (63.2%); in the endotracheal tube-
lower airway group, S. aureus (15.7%) 
and upper airway bacteria (21.1%); in the 
oropharynx-endotracheal tube-lower air-
way group, Enterobacteriaceae (70.8%) 
prevailed (P < 0.001). The mean survival 
(entrance) time to lower airways for the 
Acinetobacter / Pseudomonas / Steno-
trophomonas group was 8.28 ± 0.81 days; 
for the Enterobacteriaceae group, 5.63 ± 
0.41; and for Candida spp. group, 3.00 ± 
0.82 days (P < 0.005). 
Conclusions. Oropharyngeal contamina-
tion of the lower airways is the most im-
portant route of colonization. Different 
pathogens enter the lower airways at dif-
ferent time intervals from the insertion of 
an endotracheal tube.
Keywords: colonization, airway, intubation, 
mechanical ventilation, bronchoalveolar 
lavage, ventilator-associated pneumonia 
INTRODUCTION
Ventilator-associated pneumonia (VAP) 
still remains a common device-associated 
hospital acquired infection in pediatric 
and adult intensive care units (ICUs). Dur-
ing the last decade, a remarkable decline in 
the VAP incidence has been documented 
in economically developed countries; how-
ever, the incidence in developing countries 
is decreasing as well (1). Despite signifi-
cant improvements, there is still a lot of 
controversy on how to achieve minimal 
incidence, even knowing the pathogenesis 
of colonization of the tracheal bronchial 
tree (2-4). Sometimes the implementation 
of VAP prevention bundles in the pediat-
ric population is problematic. Likewise, 
elevation of the head by 30o–45o angle 
for an infant is even impossible, and deep 
vein thrombosis prophylaxis in the pediat-
ric population does not work in terms of 
VAP prevention. Education and training 
of nursing staff and implementation of 
adjusted “pediatric” bundles have a sig-
nificant impact on reduction in the VAP 
incidence (5). However, having a minimal 
incidence, there is still a question whether 
we can do something more. Therefore, the 
aim of our study was to determine ways of 
bacterial transmission to the lower airways 
(LA) and associated risk factors in intu-
bated patients after the implementation of 
VAP prevention bundle in a tertiary-care 
pediatric intensive care unit (PICU).
METHODS
Study population and data collection
This prospective observational study was 
conducted in a single tertiary-care PICU (8 
beds, around 50 patients intubated for > 24 
hours annually) of the Hospital of Lithu-
anian University of Health Sciences Kauno 
Klinikos from February 2012 to June 2013. 
All consecutive patients aged from 1 
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month to 18 years and intubated for >24 
hours were eligible for inclusion into the 
study. Exclusion criteria were multiple 
congenital abnormalities, chronic infec-
tion (e.g. cystic fibrosis), and mental dis-
orders. Patients exited the study at time 
of extubation, tracheostomy, and death. 
None refused to participate in the study. 
The study protocol was approved by Kau-
nas Regional Biomedical Research Ethics 
Committee and written informed consent 
was obtained on January 9, 2012 (registra-
tion No. 8/2012). 
According to the protocol, microbiological 
specimens were collected from three sites: 
oropharynx (OPX) (swabs), lumen of the 
proximal tip of an endotracheal tube (ETT) 
(swabs), and LA (bronchoalveolar lav-
age [BAL] aspirate).  The blind BAL sam-
ple was taken by inserting a single-lumen 
regular endotracheal suction catheter of 
appropriate size through an orally inserted 
endotracheal tube. Patients were preoxi-
genated with 100% oxygen. Then a suction 
catheter was inserted to a wedge position, 
instilling 1 mL/kg saline for <20 kg and 20 
mL saline for >20 kg patient, and then im-
mediately withdrawing the fluid (6-8). Any 
count of pathogens (cfu/mL) in LA was 
considered as positive, and BAL aspirate 
with ≥105 cfu/mL was defined as heavy 
colonization (9). The oropharynx was cho-
sen because its crossroad position for the 
nasopharynx, oral cavity, and hypophar-
ynx and potential endogenous source, and 
proximal tip of the ETT because of its po-
tential exogenous source of contamination 
and colonization of the tracheal bronchial 
tree (1;3;4;10) . Sets of three microbio-
logical samples were collected on the first 
day and every third consecutive day until 
day 18 and later every fifth day until day 
28. Extra sample sets were taken in the 
following seven circumstances: 1) before 
extubation, 2) after bronchoscopy, 3) gas-
trointestinal endoscopy and after patient 
transportation for investigation such as 4) 
computed tomography (CT), 5) magnetic 
resonance imaging (MRI), and 6) other or 
7) surgery outside the PICU area. A total 
of 284 sample sets (284 × 3 samples) were 
collected for 62 patients.
Microbiologic methods
Study samples were coded and sent to the 
microbiology laboratory for identifica-
tion. The samples were inoculated directly 
onto 5% sheep blood agar (BBL, USA), 
chocolate agar (BBL, USA), and MacCo-
nkey agar plates (Oxoid, UK). Sheep blood 
and chocolate agar plates were incubated 
at 35°C in an atmosphere containing 5% 
CO2 and MacConkey agar plates, at 35°C 
for 18–24 hours. If a culture was negative 
on the first observation, sheep blood and 
chocolate agar plates were re-examined af-
ter the second 24-hour incubation. Pulsed-
field gel electrophoresis (PFGE) was 
performed on all isolated pathogens by 
using the modified procedures published 
by Barth and Pitt as well as Grothues and 
Tümmler (10;11). Isolated pathogens, po-
tentially causing VAP, and others (S. pneu-
moniae, H. influenzae, S. aureus, E. coli, K. 
pneumoniae, Enterobacter cloacae, Ente-
rococcus spp., P. aeruginosa, Acinetobac-
ter spp., Stenotrophomonas maltophilia, 
Candida spp., beta-hemolytic streptococ-
ci) were identified using matrix-assisted 
laser desorption ionization-time of flight 
(MALDI-TOF, Bruker) mass spectrometry 
(MS). Disk diffusion susceptibility testing 
was performed, and zone diameters of in-
hibition were interpreted according to the 
European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) recom-
mendations. 
VAP definition and prevention in the 
PICU
VAP was identified during the routine 
surveillance procedure by using a combi-
nation of imaging, clinical, and laboratory 
criteria (pathogen concentration of ≥104 
cfu/mL in a blind BAL aspirate). Ventila-
tor-associated tracheobronchitis (VAT) 
diagnosis was based on the absence of clin-
ical and radiographic evidence of pneu-
monia and the following criteria: positive 
culture obtained by deep tracheal aspirate 
and 2 signs or symptoms with no recogniz-
able cause (fever [>38.5°C], cough, new or 
increased sputum production, rhonchi, or 
wheezing) (12;13). 
In the period from 2006 to 2007, when 
the multimodal intervention was designed 
(education of the PICU staff about VAP 
prevention and correction of daily care of 
a patient according to the evidence-based 
recommendations, feedback communica-
tion with the PICU staff in the postinter-
vention period and implementation of new 
daily care protocols), there was a sharp de-
crease in the VAP incidence (21.8 versus 
8.8 per 1000 ventilator-days) (14). Later, 
the implementation of VAP prevention 
bundle (semi-recumbent 30°–45° position 
of the head, daily evaluation of readiness 
to wean, comprehensive oral care protocol, 
periodical check for gastric overdistention, 
ETT cuff pressure between 20 and 30 cm 
of water, stress ulcer prophylaxis, periodic 
drainage and absence of tubing condensate 
and annual reporting of surveillance re-
sults in the PICU) led to a further decline 
in the VAP incidence curve (2.0 per 1000 
ventilator-days in 2012; surveillance data 
were submitted to the INICC registry) (1).
Statistical analysis
First of all, all the microbiological samples 
were analyzed and later, matched sample 
sets. A matched sample set was defined 
if there was a growth of matching patho-
gens from the LA and at least one of the 
other upper airway sites (OPX or ETT) 
at the moment of sample collection. For 
statistical analysis, all the pathogens were 
divided into five groups: Acinetobacter, 
Pseudomonas and Stenotrophomonas 
(APS); Candida spp.; Enterobacteriaceae; 
S. aureus; and bacteria of the upper airway 
(UA) with the oral cavity.
The descriptive analysis methods were 
used (mean, standard deviation, median, 
interquartile range (IQR), proportion). 
Pediatric index of mortality (PIM2) was 
used as independent descriptive variable 
for assessment of status of a patient at the 
time of his admission to PICU or the first 
face-to-face contact with PICU physician 
(15). The crosstabulation method and the 
chi-square test with an estimate of ad-
justed residual (≥ |2.0|) were used to com-
pare categorical variables among different 
subgroups. In addition, matched samples 
were tested using Kaplan-Meier survival 
analysis and the Breslow test for pairwise 
comparisons. Survival time was defined as 
the time period between ETT placement 
and entry of a matching pathogen from the 
OPX or the ETT to the LA. For all analyses, 




Among 62 orally intubated patients, there 
were 40 (64.5%) of males with a mean 
age of 7.3 years (SD=6.5) and 22 (35.5%) 
of females with a mean age of 8.6 years 
(SD=7.2). The mean PIM2 was 10.8% (me-
dian, 4.8; IQR, 7.63) (1;15). Most of the pa-
tients’ clinical characteristics are presented 
in Table 1. 
The overall colonization rates were high 
and distributed homogeneously in the 
OPX (75%–100%; (χ2 = 5.35, df = 6, P > 
0.05) and the LA (50%–76.5%; χ2 = 6.85, df 
= 6, P > 0.05). However, the ETT was colo-
nized at lower rates and the colonization 
rates differed significantly (22.2%–80%; χ2 
= 25.02, df = 6, P < 0.001). The lowest rate 
was observed on days 1–3 (28.8%, AR=-
4.2) and the highest, on days 4–6 (52.7%, 
AR=2.2), days 7–9 (61.8%, AR=2.8) and 
days 10-12 (52.9%, AR=1.2) (Table 2).  A 
total of 166 (58.5%) BAL aspirates were 
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Table 2. Colonization rates by site and time period  
All samples Sampleså Extra samples OPX ETT LA
Days N N N Positive % Positive % Positive %
1–3 160 114 46 85.0 28.8 53.5
4–6 55 29 26 81.8 52.7 60.7
7–9 34 18 16 88.2 61.8 76.5
10–12 17 9 8 94.1 52.9 52.9
13–15 9 6 3 66.7 22.2 66.7
16–18 4 4 0 75.0 25.0 50.0
19–28 5 4 1 100 80.0 60.0
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S. aureus (n = 51) 100 100 100
Klebsiella spp. (n = 31) 83.9 96.8 83.9
Enterobacter spp. (n = 19) 84.2 100 94.7
Acinetobacter spp. (n = 18) 100 63.6 100
E. coli (n = 16) 50 100 100
Candida spp. (n = 13) 92.3 92.3
Beta-hemolytic streptococci (n = 10) 90 100 100
S. maltophilia (n = 10) 0 100 40
Pseudomonas spp. (n = 8) 100 100 87.5
C. freundii (n = 4) 100 100 100
S. pneumoniae (n = 3) 100 100 100
Moraxella spp. (n = 3) 0 100
H. influenzae (n = 2) 50 100
P. mirabilis (n = 1) 100 100 100
R. ornithinolytica (n = 1) 100 100 100
E. corrodens (n = 1) 100 100
Table 4. Colonization rates by pathogen groups and matched sample groups  
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Table 5. Colonization rates by time period and matched sample groups  


















































































































Figure. Survival analysis of matched samples by pathogen groups
 
Pathogen groups All matches (n = 191) OPX-LA (n = 62) ETT-LA (n = 17) OPX-ETT-LA (n = 112)
Mean SE Mean SE Mean SE Mean SE
Enterobacteriaceae 5.63 0.41 3.50 0.64 3.00 0 6.51 0.47
S. aureus  4.31 0.63 1.64 0.39 6.25 2.01 4.75 0.81
APS 8.28 0.81 10.44 2.65 8.00 1.00 7.52 0.66
Upper airway bac-
teria 
3.42 0.73 3.75 1.12 3.00 0.82 2.67 0.88
Candida spp. 3.00 0.82 2.90 1.06 2.50 0.50 5.00 0
Overall 5.38 0.31 4.13 0.61 5.06 1.05 6.12 0.36
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positive, and in 94 (56.6%) of them, heavy 
colonization (≥105 cfu/mL) was observed.
A total of 191 matched samples were col-
lected from 46 (74.2%) of the 62 patients. 
A triple OPX-ETT-LA sample set was seen 
in 112 (58.6%) of all cases; double OPX-
LA, in 62 (32.5%); and double ETT-LA, in 
17 (8.9%). The overall picture of colonizing 
pathogens and their antimicrobial suscep-
tibility are presented in Table 3. S. aureus 
(26.7%), Klebsiella spp. (16.2%), Entero-
bacter spp. (10.0%), Acinetobacter spp. 
(9.4%), E. coli (8.4%), and Candida spp. 
(6.8%) prevailed in matched sample sets. 
Antimicrobial susceptibility rates of the 
majority of pathogens was high and ranged 
from 83.9% to 100% with the exception of 
Acinetobacter spp. susceptibility to ceftazi-
dime (63.6%), S. maltophilia susceptibility 
to ceftazidime (0%) and trimethoprim/sul-
fonamide (40%), and H. influenzae suscep-
tibility to ampicillin (50%).
The colonization rates by pathogen groups 
and matched sample groups were differ-
ently distributed (χ2 = 42.22, df = 8, P < 
0.001). In the OPX-LA group, Candida spp. 
(76.9%) and UA bacteria (63.2%); in the 
ETT-LA group, S. aureus (15.7%) and UA 
bacteria (21.1%); and in the OPX-ETT-LA 
group, Enterobacteriaceae (70.8%) were 
most frequently observed (Table 4). Analy-
sis of colonization rates by different patho-
gens showed a very similar pattern: Can-
dida spp. (76.9%) prevailed in the OPX-LA 
group; S. aureus (15.7%), in the ETT-LA 
group; and Klebsiella spp. (77.4%), in the 
OPX-ETT-LA group (χ2 = 59.01, df = 30, 
P < 0.001). A total of 106 (55.5%) BAL as-
pirates were heavily colonized (≥ 105 cfu/
mL). There was a monomicrobial growth 
in the OPX and the ETT in almost two-
thirds of the matched sample sets (n = 123, 
64.4%), but a polymicrobial growth was 
also observed (n = 68, 35.6%). Mono and 
polymicrobial growth was steady over time 
(χ2 = 3.39, df = 5, P > 0.05).
There were one VAP (OPX-ETT-LA) and 
five VAT (OPX-ETT-LA – 4, OPX- LA – 
1) cases in the matched sample group. A 
single case of VAP was caused by P. aerugi-
nosa, and VAT, by S. aureus (n = 2), Aci-
netobacter spp. (n = 1), C. freundii (n = 1) 
and Klebsiella spp. (n = 1).
The colonization rates by time groups 
and matched sample groups significantly 
differed (χ2 = 35.20, df = 10, P < 0.001). 
The occurrence of OPX-LA matched cases 
(48.2%) was significant on days 1–3. How-
ever, OPX-ETT-LA cases were frequently 
observed throughout almost all the pe-
riods (≥25%), and on days 1–3 and 7–9 
(40.2% and 91.4%, respectively) its oc-
currence was significant. There were no 
matched samples on days 16–18 (Table 5). 
The occurrences of matched samples were 
not associated with eight circumstances 
(one planned and seven extra) for sam-
ple collection (χ2 = 22.11, df = 14, P > 
0.05). The overall distribution of the first 
matched cases in matched sample groups 
by eight reasons was also homogeneous 
(χ2 = 20.77, df = 12, P = 0.05), however, 
the occurrence of the first OPX-LA case 
was significantly associated with transpor-
tation for a CT scan outside the PICU area 
(n = 6, 100%, AR = 2.1).
Overall survival analysis of matched sam-
ples showed that the mean survival time 
was the longest for APS (8.28 days, 95% 
CI 6.69–9.86) in pairwise comparisons 
between five pathogen groups, was shorter 
for Enterobacteriaceae (5.63 days, 95% CI 
4.82–6.43), S. aureus (4.31 days, 95% CI 
3.08–5.55) and UA bacteria (3.42 days, 
95% CI 2.00–4.85); and the shortest for 
Candida spp.  (3.00 days, 95% CI 1.38–
4.62) (P = 0.001–0.005) (Figure). 
Subgroup analysis also showed that the 
mean survival time in the OPX-LA sub-
group was longest for APS (10.44 days, 
95% CI 5.25–15.64) when five pathogen 
groups were compared (P = 0.01–0.029). 
The mean survival time for Enterobac-
teriaceae (3.50 days, 95% CI 2.25–4.75) 
and Candida spp.  (2.90 days, 95% CI 
0.83–4.98) was shorter (P = 0.01–0.029); 
and for S. aureus, the shortest one (1.64 
days, 95% CI 0.88–2.40) (P = 0.001–0.01). 
In the ETT-LA subgroup, there were no 
significant differences in the mean survival 
times comparing the groups by pathogens. 
In the OPX-ETT-LA subgroup, the mean 
survival time for APS was the longest (7.52 
days, 95% CI 6.2–8.81); for Enterobacte-
riaceae (6.51 days, 95% CI 5.5–7.43) and 
S. aureus (4.75 days, 95% CI 3.16–6.34) 
shorter; and for UA bacteria, the shortest 
one (2.67 days, 95% CI 0.94–4.40) (P = 
0.001–0.009).
DISCUSSION
The strength of this study was that it was 
conducted in the PICU and exclusively pa-
tients with ETTs were enrolled. An overall 
LA colonization rate was varied from 50% 
to 76.6%, and in more than 50% of the cas-
es, a bacterial count exceeded the thresh-
old of heavy colonization. In most (74.2%) 
of the participants, matching microorgan-
isms were detected in the LA and the OPX 
or/and the ETT.  Interestingly, Enterobac-
teriaceae were most frequently observed in 
the OPX-ETT-LA group, giving an expla-
nation that colonization in the OPX leads 
to LA colonization and secondary con-
tamination of the ETT. A proximal tip of 
the ETT was less frequently colonized, and 
there were no nonfermenting gram-nega-
tive bacteria (Pseudomonas spp., Acineto-
bacter spp., S. maltophilia) in the ETT-LA 
matching pathogen group. The presence of 
S. aureus and UA bacteria in the tube most 
likely shows its secondary contamination 
from the LA, because UA bacteria and 
Candida spp. at high rates and S. aureus at 
lower rates were most frequently seen in 
the OPX-LA group. Associations between 
a high colonization rate in the OPX and its 
significance in matching group formation 
suggest that the OPX was the most impor-
tant initial site before LA colonization. 
LA colonization starts from the time of in-
tubation and continues over time (16;17). 
In our study, the LA were already colo-
nized at a rate of >50% during the first pe-
riod (days 1–3) and the colonization rate 
was stable through all periods. In almost 
two-thirds of the matched cases, there 
was a monomicrobial growth in the OPX 
and the ETT, and it was steady over time. 
Therefore, we partially agree with Berdal 
et al., who proposed to use oropharyngeal 
swab surveillance data to guide empirical 
antimicrobial therapy for VAP cases in the 
ICU (17). However, in one-third of the cas-
es, in the presence of polymicrobial growth 
and different combinations of pathogens in 
OPX, a clinician can be mistaken.
Survival analysis revealed that Candida 
spp. reached the LA from the OPX dur-
ing 1.38–4.62 days on average; Entero-
bacteriaceae, during 4.82–6.43 days; and; 
nonfermenting gram-negative bacteria 
during 6.69–9.86 days. Most likely in abso-
lute majority of the cases, insertion of the 
ETT allowed Candida spp. direct access to 
the LA from the OPX, because the mean 
survival time was the shortest. We cannot 
confirm entry of other pathogens to the LA 
at the moment of oral endotracheal intu-
bation. We suggest their later entry to the 
LA, even entry of UA and S. aureus, based 
on the results of survival analysis in latter 
subgroups.
Analysis of the reasons for sample collec-
tion or risk factors for LA colonization 
has showed that occurrence of the first 
matching OPX-LA case was associated 
with transportation for a CT scan outside 
the PICU. This could be explained by in-
creased leakage near the cuff due to slight 
movements of the ETT during transpor-
tation, suggesting better preventive oro-
pharyngeal and deep hypopharyngeal 
suctioning of secretions and cuff pressure 
monitoring before transportation of pa-
tients in the future.
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In the literature, there is an ongoing de-
bate about the importance of LA coloni-
zation while an intubated patient stays in 
the ICU (4;9;18). Colonization, VAT, and 
VAP seems to be integral parts of one pro-
cess (9;19). In our study, only few cases of 
VAT and VAP were diagnosed. A single 
VAP case met the criteria; however, only 
one VAT case met the criteria described by 
Craven et al., because we did not use the 
quantitative criteria defining VAT in our 
surveillance system (4;12;18). Risk factors 
for VAP are well described and preven-
tive bundles have been proposed based on 
these data (20-22). However, leakage near 
the endotracheal cuff remains the main 
bridge between the OPX and the LA, caus-
ing colonization, VAT, and VAP. Preven-
tion of leakage still remains a big challenge 
in the care of a critically ill patient (5). In 
the PICU, cuff pressure measurements are 
crucial (5;23;24), because an application of 
subglotic secretion drainage (SSD) is lim-
ited due to smaller tube sizes used (ETT 
tubes <5 mm in diameter with a SSD port 
are not produced), despite evidence about 
SSD benefit in VAP prevention. The clini-
cal benefit of ETT with taper-shaped cuffs 
and silver-coated ETT still needs to be 
proved (5;25). 
Interestingly, in our study we have not de-
tected highly resistant or multidrug-resist-
ant pathogens in the LA, and an overall an-
timicrobial susceptibility picture was even 
better than we expected. Limitation of our 
study is that we have not investigated the 
influence of antimicrobials on the colo-
nization of OPX, ETT, and LA. However, 
we are sure that our colonization data can-
not be biased by antimicrobials, because 
OPX and LA colonization rates remained 
steady over a study time and antimicrobial 
susceptibility rates were high and mortal-
ity rate was low, indicating efficacy of the 
antimicrobial stewardship program in the 
PICU.
In conclusion, oropharyngeal contamina-
tion of the lower airways is the most im-
portant route of colonization. Different 
pathogens enter the lower airways at differ-
ent time intervals from the moment of en-
dotracheal tube placement. Reduction of 
leakage near the endotracheal cuff remains 
challenging in the PICU, and meticulous 
care of the oropharynx and endotracheal 
cuff pressure monitoring are advised be-
fore transportation of an intubated patient.
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